Showing 2671-2680 of 3315 results for "".
- New Genetic Mutation Behind Childhood Glaucoma Identifiedhttps://modernod.com/news/new-genetic-mutation-behind-childhood-glaucoma-identified/2481303/An international team led by Harvard Medical School scientists at Mass Eye and Ear and Boston Children’s Hospital has discovered a new genetic mutation that may be a root cause of severe cases of childhood glaucoma, according to a Harvard Medical School research
- Improved PC-IOL Technology is Key to Recent and Future Premium Cataract Surgery Growthhttps://modernod.com/news/improved-pc-iol-technology-is-key-to-recent-and-future-premium-cataract-surgery-growth/2481273/Presbyopia-correcting IOL technology improvements have led to almost a doubling of global units over the past 5 years and will be critical to driving future growth over the next 5 years, according to a Market Scope report. In 2022, PC-IOLs will represent nearly 55 percent of premi
- Opus Genetics Receives FDA Clearance of IND Application for Gene Therapy Candidate for Rare Inherited Retinal Disease LCA5https://modernod.com/news/opus-genetics-receives-fda-clearance-of-ind-application-for-opgx-001-a-gene-therapy-candidate-for-the-treatment-of-rare-inherited-retinal-disease-lca5/2481268/Opus Genetics announced the FDA has cleared its investigational new drug (IND) application for a phase 1/2, first-in-human clinical trial of OPGx-001 in patients with Leber congenital amaurosis (LCA) resulting from biallelic mutations in the LCA5 gene (LCA5). OPGx-001 is an adeno-a
- Ripple Therapeutics Appoints Jonathan Talamo, MD, to Chair of the Boardhttps://modernod.com/news/ripple-therapeutics-appoints-jonathan-talamo-md-to-chair-of-the-board/2481265/Ripple Therapeutics announced that Jonathan Talamo, MD, has been appointed as the new Chair of its Board of Directors. Dr. Talamo is internationally known as an experienced surgeon and thought leader in ophthalmology. Following 25 years in clinical practice, Dr. Talamo s
- Graybug and CalciMedica Enter Into Definitive Merger Agreementhttps://modernod.com/news/graybug-and-calcimedica-enter-into-definitive-merger-agreement/2481257/Graybug Vision and CalciMedica announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on further developing CalciMedica’s lead product candidate Auxora, a proprietary, intr
- GenSight Biologics Announces Publication of Results of Lumevoq REFLECT Pivotal Clinical Trialhttps://modernod.com/news/gensight-biologics-announces-publication-of-results-of-lumevoq-reflect-pivotal-clinical-trial/2481250/GenSight Biologics announced that the neurology journal BRAIN has published efficacy and safety findings at 1.5-year post-treatment in ND4-LHON patients treated with lenadogene nolparvovec (Lumevoq) from the REFLECT pivotal clinical trial. The REF
- ViaLase Makes Several Appointments to its Executive Teamhttps://modernod.com/news/vialase-makes-several-appointments-to-its-executive-team/2481244/ViaLase announced the appointments of Tom Frinzi as Executive Chairman of the Board; Richard Lewis, MD, as Chief Medical Officer; Shawn O'Neil as Chief Commercial Officer; and Brendan O'Herlihy as Vice President, Global Commercial Operations. The executives w
- EssilorLuxottica Supports New WSPOS Independent Medical Education Program on Myopia Managementhttps://modernod.com/news/essilorluxottica-supports-new-wspos-independent-medical-education-program-on-myopia-management/2481243/EssilorLuxottica announced it is supporting the World Society of Paediatric Ophthalmology and Strabismus (WSPOS) independent medical education program on myopia management, as a gold level supporter, which will be launched on November 19 and 20, at 2-4pm GMT. The key goals of this progr
- Luminopia Announces Oversubscribed Seed Extension Financing Round to Fund Amblyopia Treatmenthttps://modernod.com/news/luminopia-announces-oversubscribed-seed-extension-financing-round-to-fund-amblyopia-treatment/2481237/Luminopia, a prescription digital therapeutics company developing a new class of treatments for neuro-visual disorders, announced an oversubscribed $5.7M seed extension financing round. The company will be using the funding for a staged rollout of its lead product for amblyopia to pediatric
- Aviceda Announces Additional Members to its Clinical Advisory Board to Support its Clinical Development Strategy in Ophthalmologyhttps://modernod.com/news/aviceda-announces-additional-members-to-its-clinical-advisory-board-to-support-its-clinical-development-strategy-in-ophthalmology/2481232/Aviceda Therapeutics, a clinical-stage biotech company focused on developing the next generation of immuno-modulators, announced the addition of ophthalmic key opinion leaders to its clinical advisory board. The new additional Aviceda Clinical Advisory Board members are: